In short
Clinical trials are investigating HSP-CAR30 in people with relapsed or refractory CD30+ lymphoma, including classical Hodgkin lymphoma and non-Hodgkin T-cell lymphoma. These studies aim to evaluate safety, dose-limiting toxicity, and early response after infusion. The main trial is in phase 1/2.
Key points
- HSP-CAR30 is being studied in an authorised phase 1/2 clinical trial for people with relapsed or refractory CD30+ lymphoma. The trial includes classical Hodgkin lymphoma and non-Hodgkin T-cell lymphoma. Researchers are mainly checking safety, dose-limiting toxicity, and early response after infusion. The study plans to enroll 40 patients. Response is measured with RECIL 2017 criteria, and safety is tracked closely during the first month after infusion.
Clinical trial overview
This authorised interventional study is testing HSP-CAR30 in people with relapsed or refractory CD30+ lymphoma.
The trial includes classical Hodgkin lymphoma and non-Hodgkin T-cell lymphoma that are CD30+.
The brief study goal is to evaluate the safety and toxicity of HSP-CAR30 cell administration.
Who the trial is for
The trial is for patients with disease that is either relapsed or refractory.
Relapsed means the cancer came back after treatment, while refractory means it did not respond well to treatment.
Only patients who receive the infusion of HSP-CAR30 cells can be evaluated for response.
Patients who do not have detectable disease by PET-CT in the 30 days before infusion are not counted in the response analysis.
Study design and phase
This is an interventional study, which means the research team gives a treatment and then watches what happens.
The trial is in phase 1/2, so it is designed to look at early safety and early signs that the treatment may help.
The planned enrollment is 40 patients.
What the trial measures
The main safety endpoint is dose-limiting toxicity (DLT), which means side effects serious enough to limit the dose that can be given.
Researchers will calculate the proportion of patients with DLT in the first month after infusion, with a 95% confidence interval.
The study also collects data on the type and frequency of adverse events (AEs) from infusion until 30 days later.
Another endpoint is response, measured as the percentage of responses, including RC, RP, and RG, using RECIL 2017 criteria.
Response analysis is only for patients who actually receive HSP-CAR30 cells.
Treatments used in the study
The intervention list includes HSP-CAR30 and several other medicines given by intravenous infusion.
These include Fludarabina Accord, Levact, RoActemra, and Genoxal, all listed as infusion treatments in the trial data.
The source data does not give more detail on how each of these medicines is used in the study, so the main focus here is the trial of HSP-CAR30 itself.
How results are read
The study uses RECIL 2017 criteria to judge response, which is a set of rules for measuring how lymphoma changes after treatment.
The trial also uses PET-CT before infusion to check whether disease is detectable.
These measures help researchers understand both safety and early signs of benefit in this patient group.